Pharmacoeconomic review report. Ivabradine hydrochloride (Lancora).
Ivabradine (Lancora) is a heart-rate regulating drug for the management of heart failure (HF) that acts by selectively inhibiting the If current in the sinus node. Ivabradine is indicated for the treatment of stable chronic HF with reduced left ventricular ejection fraction (LVEF) d 35% in adult pat...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK533848/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2017
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
